ALL MARKETS
FTSE 100
FTSE 250
AIM MARKET


Idorsia Pharmaceuticals Ltd.
20 announcements.
Time Ticker Company Announcement
06:12 0RQE Idorsia Pharmaceuticals Ltd
Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
06:05 0RQE Idorsia Pharmaceuticals Ltd
Idorsia assigns and transfers agreement with ReveraGen to Santhera
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United States
06:00 0RQE Idorsia Pharmaceuticals Ltd
Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia – preparation for a local registration program advancing
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia announces financial results for the first half 2020
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia establishes US commercial operations and leadership team
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia announces positive results in the second Phase 3 study of daridorexant
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia successfully completes the offering of new shares thereby securing funding for the company’s growth plan
06:00 0RQE Idorsia Pharmaceuticals Ltd
Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia announces financial results for the first quarter 2020
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia issues Notice of the 2020 Annual General Meeting of Shareholders
06:00 0RQE Idorsia Pharmaceuticals Ltd
Janssen submits European Marketing Authorization Application for ponesimod for treatment of adults with relapsing multiple sclerosis
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia announces financial results for 2019 – clinical programs advanced markedly – approaching first key results
06:00 0RQE Idorsia Pharmaceuticals Ltd
Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing of daridorexant in Japan
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel
06:00 0RQE Idorsia Pharmaceuticals Ltd
Encouraging Phase 2 data on cenerimod – Idorsia's S1P1 receptor modulator currently investigated for SLE – presented at ACR 2019
06:00 0RQE Idorsia Pharmaceuticals Ltd
Idorsia announces financial results for the first nine months of 2019